China’s Tasly Mixes Western Drug-Making Art With Herbal Work
This article was originally published in PharmAsia News
Executive Summary
China's Tianjin Tasly Pharmaceutical relies on the accepted methods of manufacturing chemical-based pharmaceuticals for use in the herbal medicine market. Tasly's Fufang Danshen Diwan pill for emergency coronary treatment was the first herbal treatment cleared by the U.S. FDA for clinical trials and accounted for $80 million of the firm's sales last year. The firm's leaders attribute the success to the firm's use of production and presentation methods, research into a medicine's molecular formula and other R&D work to make its wares more acceptable in the U.S. and European markets. (Click here for more